Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance

Key Points

• Halozyme Therapeutics has revised its FY 2025 earnings guidance to an expected earnings per share of 6.000-6.400, exceeding the consensus estimate of 5.970.
• The company also provided revenue guidance of $1.3 billion-$1.4 billion, slightly above the consensus revenue estimate of $1.3 billion.
• Analysts have mixed ratings for Halozyme, with one "Strong Buy," five "Buy," four "Hold," and two "Sell" ratings, reflecting a consensus rating of "Hold" with a target price of $69.89.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 6.000-6.400 for the period, compared to the consensus earnings per share estimate of 5.970. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

Analyst Ratings Changes

A number of brokerages have issued reports on HALO. JPMorgan Chase & Co. upped their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Morgan Stanley raised their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Monday, August 18th. Finally, JMP Securities upped their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $69.89.

Halozyme Therapeutics Trading Up 0.1%

Shares of HALO opened at $73.34 on Wednesday. Halozyme Therapeutics has a 1-year low of $42.01 and a 1-year high of $79.50. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 0.40 and a beta of 1.19. The firm's 50-day moving average price is $69.65 and its 200-day moving average price is $61.77. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the business earned $0.91 EPS. The business's revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,227 shares of company stock valued at $5,870,115 in the last three months. Company insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. EverSource Wealth Advisors LLC increased its holdings in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 174 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $195,000. Daiwa Securities Group Inc. lifted its position in Halozyme Therapeutics by 919.0% during the second quarter. Daiwa Securities Group Inc. now owns 4,025 shares of the biopharmaceutical company's stock valued at $209,000 after purchasing an additional 3,630 shares during the period. Optimist Retirement Group LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at $292,000. Finally, Diversify Advisory Services LLC lifted its holdings in shares of Halozyme Therapeutics by 11.7% during the 2nd quarter. Diversify Advisory Services LLC now owns 6,929 shares of the biopharmaceutical company's stock valued at $360,000 after buying an additional 727 shares during the period. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.